As shown in Fig. 6d, e, although the percentage of tumor-infiltrating CD3+ T cells was increased to 11.0% of CD45+ lymphocytes after anti-PD-L1 antibody treatment, NPTyr-αPD-L1 group showed higher tumor infiltration of CD3+ T cells (13.9% of CD45+ lymphocytes). This evidence concerns the gene PTPRC and neoplasm.